Celltrion, Inc. Stock Korea S.E.
Equities
068270
KR7068270008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- KRW | - |
Apr. 24 | Market Share of Celltrion’s Remsima Rises to 74% in Europe | MT |
Apr. 17 | Celltrion, Inc. announces an Equity Buyback for 436,047 shares. | CI |
Sales 2024 * | 3,428B 2.49B | Sales 2025 * | 4,172B 3.03B | Capitalization | 36,605B 26.61B |
---|---|---|---|---|---|
Net income 2024 * | 505B 367M | Net income 2025 * | 1,099B 799M | EV / Sales 2024 * | 10.9 x |
Net Debt 2024 * | 656B 477M | Net Debt 2025 * | 297B 216M | EV / Sales 2025 * | 8.85 x |
P/E ratio 2024 * |
70.7
x | P/E ratio 2025 * |
32.9
x | Employees | - |
Yield 2024 * |
0.24% | Yield 2025 * |
0.25% | Free-Float | 63.31% |
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jae-Sik Lee
BRD | Director/Board Member | 66 | - |
Dong-Il Kim
BRD | Director/Board Member | 65 | 08-07-16 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B | |
-16.98% | 10.07B |
- Stock Market
- Equities
- A068270 Stock
- 068270 Stock